share_log

bluebird bio | 4: Statement of changes in beneficial ownership of securities-Director Vachon Mark

bluebird bio | 4: Statement of changes in beneficial ownership of securities-Director Vachon Mark

bluebird bio | 4:持股變動聲明-董事 Vachon Mark
美股SEC公告 ·  2024/11/08 13:14

Moomoo AI 已提取核心訊息

On November 6, 2024, Mark Vachon, associated with bluebird bio, Inc. [BLUE], was granted 24,900 shares of common stock at no cost. This transaction, which was completed on the same day, increased Vachon's direct holdings in the company to a total of 49,941 shares. The grant is part of the company's stock-based compensation program and reflects a direct ownership interest in the securities.
On November 6, 2024, Mark Vachon, associated with bluebird bio, Inc. [BLUE], was granted 24,900 shares of common stock at no cost. This transaction, which was completed on the same day, increased Vachon's direct holdings in the company to a total of 49,941 shares. The grant is part of the company's stock-based compensation program and reflects a direct ownership interest in the securities.
2024年11月6日,與藍鳥生物公司(bluebird bio, Inc. [BLUE])相關的馬克·瓦申(Mark Vachon)免費獲得了24,900股普通股。這項交易於同一天完成,將瓦申在公司的直接持股增至總共49,941股。這次授予是公司股權激勵計劃的一部分,反映了對證券的直接所有權利益。
2024年11月6日,與藍鳥生物公司(bluebird bio, Inc. [BLUE])相關的馬克·瓦申(Mark Vachon)免費獲得了24,900股普通股。這項交易於同一天完成,將瓦申在公司的直接持股增至總共49,941股。這次授予是公司股權激勵計劃的一部分,反映了對證券的直接所有權利益。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息